Following our initial findings that pretreatment of breast cancer cells with an LSD1 inhibitor rendered them more vulnerable to doxorubicin treatment, we employed knock-down and overexpression experiments and confirmed LSD1’s involvement in the chemoresistance of these cells. The gene discussed is KDM1A; the disease is breast cancer.